for earnings Lisa all Thank is just second Thank my of you you. as webcast of the And heard, XXXX. Conte. all our joining welcome you. for quarter And to you name
will initiatives milestones. of Jaguar high-level a our overview key companies, near-term call the and like I'd today's on to and I then updates begin family provide with of
of Carol Officer the a comments, XXXX. Jaguar's recap quarter for results will my of provide the Financial second Lizak, Following key financial detailed Chief
we're XXXX year. in alert, quarter net very increased the that the versus report this pleased QX revenue spoiler to first Although, XX% of
developing on company There animals, GI is medicines range derived a of with a company, diarrhea. areas use when novel from commercial distress, word sustainably stage we rainforest bowl, if today. the plants and focusing as is overactive you know primarily, the introducing from is which proprietary I'm specifically Jaguar, pharmaceuticals prescription people interpretations lexicon fresh for
With bowl, chronic, as health. disrupting to all some or debilitating, systems refer the watery incontinence, disturbing also and quality we and GI include to terminology, their patient, overactive such unpredictability, the of life, as loose, diarrhea, their GI urgency will and and stools
CIOB prescription Jaguar Napo commercializing I'll wholly now and review the candidate also develop. OnTarget the on Napo is clinical cancer for Pharmaceuticals' drug to; owned preventative crofelemer to study, adults pivotal to of developing get of CIOB, the relationship trial pharmaceuticals human all used Pharmaceuticals, family chemotherapy-induced companies, subject that Jaguar, we is on focuses the by our overactive the Phase ongoing X targeted therapy. bowel, of start the acronym product treatment going that we're with and in
plants and novel prescription prescription And focused crofelemer-related. rare Milan, diseases. on for Health, Napo indications, business. and is doing recently on as non- is focused access company, derived our for Biosciences Therapeutics small Animal a animal Jaguar products, Italian to and health Napo as Pharmaceuticals, is Magdalena Health by formed earlier-stage developing in corporation Napo family joint portion Jaguar focuses XXXX, non-prescription mental Europe in crofelemer on pharmaceuticals then a Jaguar Jaguar venture in established expanding opposed Health, Therapeutics, commercializing Italy an of medicines business Filament specifically developing from and
that with approved anti-secretory U.S. relief is prescription crofelemer, name, in chloride the human adult noninfectious our reminder, in of symptomatic is generic The brand-named a HIV/AIDS ion the indication label. the patients diarrhea a As of drug commercialized initially on channel specialty It's Mytesi. antiretroviral therapy, name brand is for Mytesi. first-in-class product, crofelemer,
the As specialty the FDA, implies, it's first indication The that's a market the was primarily States. relatively small why the and crofelemer. fast-tracked indication United by for this term reason market is in the FDA-approved
sustainably natural, approved plant-based, by harvested, to practical of fair it's under oral bring botanical is organic, only guidance. prescription it's under no drug the is guidance. trade, Mytesi, the Crofelemer, it a to pathway generic the and botanical is it's it's FDA market crofelemer There version
position funds patents associated the pharmaceutical and very non-dilutive other like So, all with in have expense talking we in when and terminal that, for discussions, license an any come that's net addition corporate to we're we factor does, we're a potential value, the all into exclusivity company. and the just forever. company And example, partnerships, essentially powerful and present to fee, about value, filed,
are unencumbered discussions global so there and to occur when and have these development actually come going always going consciousness. you the rights to never to activities crofelemer, are business public and know on, We
And small-cap that we for biotech today. events are the clinical next feel we major what corner, we the major, months, opportunities around that of market blockbuster up literally undeniably is to state this most is the fortunate, year, this the opportunities. are, two pipeline have takeaway While horrible important at Jaguar transformative couple at in take in coming and a message present, from
will be it two company recognition assistance. for events and say I'll we major And transformative late-stage again; patient which clinical value feel
patients. opportunities needs on and financial focus the patients all foremost, for otherwise. a help and And the clinical follows benefits events address late-stage from major company, are the to neglected what stakeholders are these to in medical First
HIV a beyond really a frequently is indications. powerful follow-on has I expanded crofelemer potential Crofelemer within it about product. As is that what's the indications be say, multiple to pipeline the to
all We cancer on potential used CIOB, therapy-related we're to focusing chemotherapy-induced referring are can't and acronym which ones which are CIOB, to been we on going now and the previously prioritized overactive diarrhea. as indications that so have bowl, time, to, have same at the focus
failure syndrome intestinal days on are with a failure. indications, with up microvillus patients for So, where let followers. SBS, and medical for situations to hours rare our and bowel end inclusive week. link disease, MVID two therapy-related cancer to up for now parenteral they short a referred more nutrition MVID, me as short CTD, catastrophic long-term bowel And diarrhea total make day, intestinal syndrome, that inclusion XX a CIOB. seven disease
currently for are There approved MVID. no drug treatments
thrilled of we the severe announce were for crofelemer and last patient for the and FDA an activated MVID, with treatment application investigational the a week, IND drug our FDA SBS a to new distressful As for diarrhea situation. approved physician
managing has a so to We so impact health grateful who quality these that situations, benefit opportunity are only also difficult not the crofelemer under are dramatic life. patients really of an
for October from making line results call, indication are to from to late same is a treatment the clinical crofelemer treat an comorbidity the paramount available completed in completion XXXX. the last year journey as expected Our this overactive CIOB. our milestone pivotal Phase of literally OnTarget currently this pivotal to Again, OnTarget, the results for in in this CIOB. of formulation messages indication Mytesi of chemotherapy-induced of top one of line Mytesi the And takeaway for patient to on the of trial important activity year the important follow-on trial market, X We've neglected Mytesi, this near-term our this top bowel. potentially enrollment preventative of of most expand
with A of the cancer in basket we have solid OnTarget treatment our oral the real-world cytotoxic first participation because standard a and clinical support targeted or drug of patients preventative situation diversity CIOB, -- is [indiscernible] management tumor approval It XX% that diarrhea which and its childhood paradigm-shifting include to on with for the of a without to targeted goal being label, trial. multiple trial works In all typically patient. first types trial therapies for the greater grade adult includes than that call administered obtaining the label, of chemotherapy kind. than is first FDA of their therapy a
the where patient targeted prophylactic their to in this the chemotherapy-induced is example, curative treatment established If of trial often vomiting referred to, compare protocols And the use, that metastatic the first and for is is years, both and the as and which preventative essentially you and -- it CINV. for months way, situation nausea for rest are therapy by a lives potentially the for with treating situation. we
in Treatment occurs days a the cytotoxic three treatment typically with CINV protocol. limited for first chemotherapy
the bowel an cases the projected estimated XXXX. length dramatically in is treatment. from cancer new this overactive U.S. the in million chemotherapy-induced There CINV X.X terms is of a of CIOB different year situation So, nausea for
are comparable for prophylactic And taken of that's iHealthcareAnalyst. those is X market firm reach months of global approximately research CINV cytotoxic Again, chemo. so the outside to value the by products indication or billion approximately days the six for The from market an a according of duration projected XXXX. $X.X for to
patient's months sometimes hopefully essentially and of studying OnTarget CIOB from for chronically rest of and the design the day is The of administered every quality treatment and years for life. study extended targeted therapy preventive
therapy, the to of opportunity similarity address way. preventative affecting to compliant is the care their important for patient assist the cancer anti-cancer the the potentially stay positive in patient's a Another outcome treatment and with
A who the who for terminology CINP, of home to CINV, have Neuropathic I also back stools am month, going the benefits shift CIOB, labeling is which patient the happen unpredictable. as watery once which to surprised disrupting a patient the patient unsettling, severe daily. a chaining as but deals with diarrhea to as dealing heard lexicon the preventative and similar week, refer the you Chemotherapy-Induced could well unpredictable, once their Essentially, might to Pain. be with
well isolating, being diagnosis can with to the circumstances therapies embarrassing, Both impact patients of in as person as therapies. and other with health the well cancer dignity the be and compliance the and anti-cancer
you on-board for mitigate to until want of seizure. As treatment think treat impact an of prevent wait to analogy, to therapy epilepsy. don't on preventative and/or the occurs the seizure We
range advertise where That's age therapies. landscape to think dozens has now are targeted the of treatment targeted therapies, how or of full approved CIOB. the companies direct wonderfully consumers. you treatment There targeted habitually seeing preventative episodes advertisements of new for are changed, Cancer therapies the about pharmaceuticals of where of we in the
flow the exact occurs the of to excess normalizes mechanism the the diarrhea and into intestines Most of channel active secretion ions the secretory that of the of the By therefore gut cause ions' of which following chloride unique all if and mechanism flow, that then chloride fluids diarrhea the when oversecretion chloride disruption intestine is and gastrointestinal anti-secretory The is watery action, follows, the crofelemer a by caused behavior. of normalize intestinal active the Crofelemer into normalizes. secretion gut, first-in-class into into that water modulator. osmosis ions that novel normalizing crofelemer's not so, fluids occurs. gut the by
back situation intestine orally, normalizes it I over-activation, the normalizes clog is the which the Crofelemer gut, meaning it that and into it goes normalcy. up into it it normalizes and that described. intestines in the taken the It water It brings flow or fluid to doesn't block and over-activation, just acts as locally up. of
antidiarrheal, When constipation. and of work you taken by such think think are essentially mechanism the and a of constipated typically as historically, episode And Loperamide, occurs. which are These diarrhea Imodium typically, chronically. products, opioids, of you stay can't after you obviously, products they
an in the not because Crofelemer and that secondary opioid, risk on. of gut, is have drug-drug any it does crofelemer locally problems Crofelemer doesn't known not interactions. constipation, acting later metabolites have therefore is causing have doesn't
an is You not so antibiotics part managing don't generate. you the to from quality therapies, we it's why want have life-saving the and effect safety first-pass resistance health the don't can focus you that with the to benefit where don't a on situation, profile And and can you patient address in have their liver, and CIOB. interfere the implications antibiotic, life want come that of do complicated of
common two-year a new Though indication. example, chronic Mytesi why carcinogenesis fail is drug market product. on and safety completed, are an is manufacturing. huge for reasons applications two for we've the hallmark the The of already safety improved most already
placebo, the have in never that's now have seen on We have many market thousands product than adverse different effect and events been living HIV for profile years reported for with a label. serious and no in a side that AIDS we patients of been
throughout and treatment. That's So, data in the the again, OnTarget is what database for last indication, a from The much the this people larger trial. pharmacy October, will primary week patients come when supply October. the of rich -- neglected presentations as number benefiting. event larger, indication, a in and on top come chain a data the cancer States a line this it's we the essentially potential important the of of we full the new approval already make endpoints the the released beautiful is to for for that United and any a the of will this endpoint there's of much undergoing key that statistical from market then data, rest for transformative of secondary rainforest product significance conferences potentially of specialty that with collection in in year, a CIOB, data Mytesi, And trial completion that's of opportunity the matter for we'll out rest top next in line cancer prepare blind
that We from targeted normalization single standard therapy of while their will the successfully are again, as a targeted as provides be should cancer protocols, that part live crofelemer and patients therapies, drug the crofelemer can be should on cancer and every believe curative demonstrate trial maintain patients with. a remaining situation the in therapy, OnTarget over-activation to companion to the a either chronic situation or taken targeted day, cancer
which, and of control patients how voice, health patients not patient [digni] exist, development prescribing as which the is our also and of and This with," cancer is but And providers, the fully course, importantly, is and healthcare the word only potential choice a educational providers the throughout well, focusing to life the voice not quality benefits common payers. addressing (ph), treatment, are life power live is, for And of there on highlight, of in infused for the undergoing the live. of to here very planning. important just key important "Live
that living go to will a therapies because diarrhea, people bowel. side targeted XX% show loose with the effect OnTarget overactive about the of of cancer go sub-therapeutic time, or off stools, saving dose life watery their therapy Publications of
as care we're living as can water better with times they as today support chemotherapy this for that known take shown cancer And loose preventing patients outcomes. as bowel, treatment diarrhea, otherwise about cancer overactive better adherence and to it's targeted diarrhea introducing So, and of suffer costs from treatment been induced of type it stools, much therapies people three to well. when
MVID crofelemer a different newborns threatening concentrated diarrhea. failure, life rare to product now secretory rare even novel to globally, autosomal a for and and ultra estimated severe disease two so, children hundred couple death discuss is of from and prioritize powder than Jaguar's formulations, I'll morbidity, investigative highly oral indications significant Mytesi. a leading yet crofelemer, disease recessive intestinal a affect and
nutrition, a complications. with no can of therapeutic the nutrition approved of of for which VNIV, or currently are for of multiples there MVID While cost the parental delivery around management is of treatments standard MVID, total $XXX,XXX year, care life that the
reduce and MVID host patients value greater suffer nutrition. from and and diarrhoea the pediatric rare this near dependence intestinal failure with We to symptomatic plan ultra the MVID a severe gastroenterologists, leading future cholera in like their management on patients parental understanding an of disease. elaborate of diarrhoea may MVID with in bring further daily managing to investor facing webinar diarrhoea
SBS is referred is which nutrition. crofelemer volume, Syndrome, treated the measures. providing Jaguar for at studies designation Agency here for stool States. for as Orphan Investigator approved FDA been product EMA the XX% looking crofelemer also Crofelemer and by regions, of with supporting Bowel with and in been the We'll by are and metabolic improved EU FDA United Short endpoint. Drug to granted and physician parental the also for accepted the regulatory MVID has has failure the MVID known for parental with formation, reducing an goal other an Orphan intestinal and European Medicines to dependence failure patient stool an IND end proof-of-concept Drug SBS also and granted the intestinal in MENA of be We're nutrition XX% designation on SBS about FDA with SBS. EMA by patients Initiative
the conditions programs cost of investigations Bowel such or to Syndrome providing not debilitating early crofelemer could early specific potentially EU In both, MVID, published high for do patient reimbursed in impacting XXXX reimbursement support access needs. Short these exist of for the while opportunity data which with accordance and for from in United of and chronic or clinical neglected access States these an care countries the guidelines morbidity
for a mortality, us patients corner a clinical we the both affect stakeholders. Therapeutics for access again, event, ground, able was to high and able high benefit advocacy rare day, and be the rest And major to transformative opportunity clinical have access XX Europe of And event the products expense, high patient access estimated a in XXXX, have our around the feet disease opportunities SBS day, lives. is for patients for these rare for single establishing cases catalyst active patients some impetus to major toxic late-stage that patient for an very XX,XXX the early Syndrome it's second what a these model. is the to Napo in these on essentially diseases to feel the is patients Short be hours XXXX. in their and all to toxic, typical in Bowel There And nutrition expensive very around so every parental the world, group. morbidity, patients require business
is again, XXXX. is, to by parental disease the Vision $X.X The global firm, patients growth SBS rare the $XX SBS these studies Reports. to nutrition. And is standard-of-care business It's models. approximately billion population the at for time Other in in this to to This market grow of are billion. third-parties put fact, Research market research projected; the projected
CIOB of MVID initial So, year. for countries. of patient for failure expect X support or Phase early European in in of SBS with evidence intestinal participation last results trial either proof-of-concept from crofelemer year to patients of we access top the end before with expect the our the the And have in recap and certain week of Chemotherapy-induced we October to line prophylaxis overactive here, bowel, this
XXXX. in So, late-stage on in important generations revenue results potentially based both these clinical XXXX
at I'd let will you address to can that and any a the submitted website hand participating the know we They have is writing. segment Webcast today's for Webcast discussion CFO, and URL Events submitted that over in jaguar.health. end to Relations Investor of section of questions like all on Carol, of brief Presentations the the the Q&A Web page event be today Jaguar's link the via site I Before our to our the of appears for
now move Carol, along XXXX. to we'll financial And key over quarter for to you. it results of I'll turn the second the
